drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00906 | DB09098 | 1,567 | 98 | [
"DDInter1801",
"DDInter1700"
] | Tiagabine | Somatrem | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1567,
24,
98
]
],
[
[
1567,
24,
159
],
[
159,
63,
98
]
],
[
[
1567,
63,
1419
],
[
1419,
24,
98
]
],
[
[
1567,
24,
384
],
[
384,
... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatin... |
DB00065 | DB01235 | 581 | 1,191 | [
"DDInter923",
"DDInter1054"
] | Infliximab | Levodopa | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier[Label]. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prev... | Moderate | 1 | [
[
[
581,
24,
1191
]
],
[
[
581,
25,
1307
],
[
1307,
40,
1191
]
],
[
[
581,
25,
63
],
[
63,
24,
1191
]
],
[
[
581,
24,
148
],
[
148,
... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levodopa"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Melphalan"
],
[
"Melphalan",
... | Infliximab may lead to a major life threatening interaction when taken with Melphalan and Melphalan (Compound) resembles Levodopa (Compound)
Infliximab may lead to a major life threatening interaction when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00691 | DB00959 | 1,058 | 1,486 | [
"DDInter1237",
"DDInter1191"
] | Moexipril | Methylprednisolone | Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney prob... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
1058,
24,
1486
]
],
[
[
1058,
63,
175
],
[
175,
40,
1486
]
],
[
[
1058,
24,
167
],
[
167,
1,
1486
]
],
[
[
1058,
24,
617
],
[
617,
... | [
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Moexipril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB01232 | DB01309 | 1,327 | 1,254 | [
"DDInter1640",
"DDInter933"
] | Saquinavir | Insulin glulisine | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1327,
24,
1254
]
],
[
[
1327,
24,
1033
],
[
1033,
63,
1254
]
],
[
[
1327,
64,
1424
],
[
1424,
24,
1254
]
],
[
[
1327,
63,
167
],
[
167... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
... | Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Saquinavir may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a... |
DB00468 | DB04948 | 1,424 | 1,084 | [
"DDInter1557",
"DDInter1083"
] | Quinine | Lofexidine | An alkaloid derived from the bark of the cinchona tree. It is used as an antimalarial drug, and is the active ingredient in extracts of the cinchona that have been used for that purpose since before 1633. Quinine is also a mild antipyretic and analgesic and has been used in common cold preparations for that purpose. It... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1424,
24,
1084
]
],
[
[
1424,
23,
112
],
[
112,
23,
1084
]
],
[
[
1424,
63,
618
],
[
618,
24,
1084
]
],
[
[
1424,
24,
774
],
[
774,
... | [
[
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"... | Quinine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Quinine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may... |
DB11817 | DB14004 | 1,259 | 398 | [
"DDInter165",
"DDInter1806"
] | Baricitinib | Tildrakizumab | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis . The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psorias... | Major | 2 | [
[
[
1259,
25,
398
]
],
[
[
1259,
62,
1114
],
[
1114,
23,
398
]
],
[
[
1259,
64,
58
],
[
58,
24,
398
]
],
[
[
1259,
63,
200
],
[
200,
... | [
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tildrakizumab"
]
],
[
[
"Baricitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
"Zinc ... | Baricitinib may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Tildrakizumab
Baricitinib may lead to a major life threatening interaction when taken with Alefacept and Alefacept may cau... |
DB00189 | DB00682 | 459 | 126 | [
"DDInter691",
"DDInter1951"
] | Ethchlorvynol | Warfarin | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Minor | 0 | [
[
[
459,
23,
126
]
],
[
[
459,
24,
1376
],
[
1376,
40,
126
]
],
[
[
459,
24,
593
],
[
593,
63,
126
]
],
[
[
459,
24,
1376
],
[
1376,
... | [
[
[
"Ethchlorvynol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine (Compound) resembles Warfarin (Compound)
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interactio... |
DB00047 | DB00397 | 176 | 1,466 | [
"DDInter932",
"DDInter1458"
] | Insulin glargine | Phenylpropanolamine | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor. It has been used as a decongestant and appetite suppressant. Currently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. | Moderate | 1 | [
[
[
176,
24,
1466
]
],
[
[
176,
24,
73
],
[
73,
25,
1466
]
],
[
[
176,
24,
1178
],
[
1178,
63,
1466
]
],
[
[
176,
24,
999
],
[
999,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylpropanolamine"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phente... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Phenylpropanolamine
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazi... |
DB00280 | DB00816 | 494 | 1,674 | [
"DDInter575",
"DDInter1346"
] | Disopyramide | Orciprenaline | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Major | 2 | [
[
[
494,
25,
1674
]
],
[
[
494,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
494,
24,
251
],
[
251,
23,
1674
]
],
[
[
494,
24,
617
],
[
617,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v... | Disopyramide (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken w... |
DB00773 | DB11757 | 896 | 960 | [
"DDInter702",
"DDInter994"
] | Etoposide | Istradefylline | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly in... | Moderate | 1 | [
[
[
896,
24,
960
]
],
[
[
896,
24,
77
],
[
77,
24,
960
]
],
[
[
896,
63,
134
],
[
134,
24,
960
]
],
[
[
896,
62,
147
],
[
147,
24,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vin... |
DB00712 | DB00761 | 1,274 | 1,621 | [
"DDInter763",
"DDInter1497"
] | Flurbiprofen | Potassium chloride | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | A white crystal or crystalline powder used as an electrolyte replenisher, in the treatment of hypokalemia, in buffer solutions, and in fertilizers and explosives. The FDA withdrew its approval for the use of all solid oral dosage form drug products containing potassium chloride that supply 100 mg or more of potassium p... | Moderate | 1 | [
[
[
1274,
24,
1621
]
],
[
[
1274,
21,
28809
],
[
28809,
60,
1621
]
],
[
[
1274,
24,
1338
],
[
1338,
63,
1621
]
],
[
[
1274,
63,
831
],
[
8... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Potassium chloride"
]
],
[
[
"Flurbiprofen",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Eff... | Flurbiprofen (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Potassium chloride (Compound)
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause a moderate interaction that could exacerbate diseas... |
DB01221 | DB12015 | 1,190 | 1,033 | [
"DDInter1007",
"DDInter53"
] | Ketamine | Alpelisib | Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1190,
24,
1033
]
],
[
[
1190,
63,
1264
],
[
1264,
24,
1033
]
],
[
[
1190,
24,
351
],
[
351,
24,
1033
]
],
[
[
1190,
24,
1619
],
[
1619... | [
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Ketamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Dox... | Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Ketamine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may ca... |
DB00400 | DB01072 | 353 | 915 | [
"DDInter843",
"DDInter129"
] | Griseofulvin | Atazanavir | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses p... | Moderate | 1 | [
[
[
353,
24,
915
]
],
[
[
353,
24,
1327
],
[
1327,
1,
915
]
],
[
[
353,
6,
8374
],
[
8374,
45,
915
]
],
[
[
353,
21,
28714
],
[
28714,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
]
],
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
... | Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir (Compound) resembles Atazanavir (Compound)
Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Atazanavir (Compound)
Griseofulvin (Compound) causes Asthenia (Side Effect) and Asth... |
DB00694 | DB15965 | 51 | 1,330 | [
"DDInter485",
"DDInter1270"
] | Daunorubicin | Naxitamab | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Moderate | 1 | [
[
[
51,
24,
1330
]
],
[
[
51,
24,
1532
],
[
1532,
24,
1330
]
],
[
[
51,
63,
597
],
[
597,
24,
1330
]
],
[
[
51,
25,
770
],
[
770,
24... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naxitamab"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Naxitamab
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol an... |
DB01115 | DB06616 | 336 | 594 | [
"DDInter1291",
"DDInter224"
] | Nifedipine | Bosutinib | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Moderate | 1 | [
[
[
336,
24,
594
]
],
[
[
336,
63,
883
],
[
883,
1,
594
]
],
[
[
336,
6,
8374
],
[
8374,
45,
594
]
],
[
[
336,
7,
1870
],
[
1870,
57... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib (Compound) resembles Bosutinib (Compound)
Nifedipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosutinib (Compound)
Nifedipine (Compound) upregulates MYC (Gene) and MYC (Gene) is downreg... |
DB01024 | DB11003 | 1,096 | 748 | [
"DDInter1252",
"DDInter100"
] | Mycophenolic acid | Anthrax vaccine | Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a c... | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1096,
24,
748
]
],
[
[
1096,
25,
676
],
[
676,
63,
748
]
],
[
[
1096,
24,
1683
],
[
1683,
24,
748
]
],
[
[
1096,
64,
1057
],
[
1057,
... | [
[
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
... | Mycophenolic acid may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab a... |
DB00835 | DB00902 | 100 | 104 | [
"DDInter245",
"DDInter1168"
] | Brompheniramine | Methdilazine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
100,
24,
104
]
],
[
[
100,
63,
13
],
[
13,
24,
104
]
],
[
[
100,
24,
820
],
[
820,
1,
104
]
],
[
[
100,
24,
537
],
[
537,
40,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB08904 | DB09036 | 375 | 812 | [
"DDInter342",
"DDInter1668"
] | Certolizumab pegol | Siltuximab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). I... | Major | 2 | [
[
[
375,
25,
812
]
],
[
[
375,
23,
1193
],
[
1193,
62,
812
]
],
[
[
375,
62,
1461
],
[
1461,
23,
812
]
],
[
[
375,
25,
287
],
[
287,
... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Siltuximab"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[... | Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Siltuximab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vit... |
DB00414 | DB00903 | 590 | 1,680 | [
"DDInter16",
"DDInter686"
] | Acetohexamide | Etacrynic acid | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as ... | Moderate | 1 | [
[
[
590,
24,
1680
]
],
[
[
590,
24,
1479
],
[
1479,
62,
1680
]
],
[
[
590,
24,
1021
],
[
1021,
63,
1680
]
],
[
[
590,
24,
1274
],
[
1274,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic a... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Etacrynic acid
Acetohexamide may cause a moderate interaction that could exacerbate diseases when take... |
DB08904 | DB11760 | 375 | 119 | [
"DDInter342",
"DDInter1742"
] | Certolizumab pegol | Talazoparib | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Major | 2 | [
[
[
375,
25,
119
]
],
[
[
375,
63,
66
],
[
66,
24,
119
]
],
[
[
375,
24,
1129
],
[
1129,
63,
119
]
],
[
[
375,
25,
713
],
[
713,
24,... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Certolizumab pegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
... | Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Huma... |
DB00023 | DB00352 | 305 | 482 | [
"DDInter127",
"DDInter1814"
] | Asparaginase Escherichia coli | Tioguanine | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
305,
24,
482
]
],
[
[
305,
24,
1299
],
[
1299,
62,
482
]
],
[
[
305,
24,
151
],
[
151,
63,
482
]
],
[
[
305,
24,
66
],
[
66,
24,... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Tioguanine
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate dise... |
DB00284 | DB09082 | 1,647 | 659 | [
"DDInter11",
"DDInter1934"
] | Acarbose | Vilanterol | Acarbose is a complex oligosaccharide that acts as an inhibitor of several enzymes responsible for the breakdown of complex carbohydrates in the intestines. It inhibits both pancreatic alpha-amylase and membrane-bound alpha-glucosidases - including intestinal glucoamylase, sucrase, maltase, and isomaltase - which are r... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
1647,
24,
659
]
],
[
[
1647,
24,
1220
],
[
1220,
23,
659
]
],
[
[
1647,
24,
323
],
[
323,
24,
659
]
],
[
[
1647,
63,
215
],
[
215,
... | [
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Acarbose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Acarbose may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide a... |
DB05679 | DB09237 | 1,683 | 1,586 | [
"DDInter1907",
"DDInter1045"
] | Ustekinumab | Levamlodipine | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Levamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication. Levamlodipine belongs to the dihydropyridine group of calcium channel blockers. This medication was first marketed in Russia and India before being granted FDA approval. The names S-amlod... | Moderate | 1 | [
[
[
1683,
24,
1586
]
],
[
[
1683,
63,
1648
],
[
1648,
24,
1586
]
],
[
[
1683,
25,
908
],
[
908,
24,
1586
]
],
[
[
1683,
24,
384
],
[
384,
... | [
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levamlodipine"
]
],
[
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
... | Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Levamlodipine
Ustekinumab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may c... |
DB00425 | DB01110 | 558 | 86 | [
"DDInter1970",
"DDInter1209"
] | Zolpidem | Miconazole | Zolpidem, also known as _Ambien_, is a hypnotic drug that was initially approved by the FDA in 1992 [FDA label]. Zolpidem improves sleep in patients with insomnia. It is aimed for use in patients with difficulties initiating sleep. This drug decreases the time to fall asleep (sleep latency), increases the duration of s... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Moderate | 1 | [
[
[
558,
24,
86
]
],
[
[
558,
6,
10215
],
[
10215,
45,
86
]
],
[
[
558,
21,
29122
],
[
29122,
60,
86
]
],
[
[
558,
24,
222
],
[
222,
... | [
[
[
"Zolpidem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
]
],
[
[
"Zolpidem",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
... | Zolpidem (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Miconazole (Compound)
Zolpidem (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Miconazole (Compound)
Zolpidem may cause a moderate interaction that could exacerbate diseases when taken with S... |
DB08870 | DB11613 | 850 | 1,519 | [
"DDInter228",
"DDInter1924"
] | Brentuximab vedotin | Velpatasvir | Brentuximab vedotin, also known as Adcetris®, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin's lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved... | Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Moderate | 1 | [
[
[
850,
24,
1519
]
],
[
[
850,
63,
1374
],
[
1374,
24,
1519
]
],
[
[
850,
24,
384
],
[
384,
24,
1519
]
],
[
[
850,
24,
351
],
[
351,
... | [
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Velpatasvir"
]
],
[
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abirater... | Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Velpatasvir
Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00341 | DB01233 | 1,242 | 1,311 | [
"DDInter343",
"DDInter1197"
] | Cetirizine | Metoclopramide | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1242,
24,
1311
]
],
[
[
1242,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1242,
24,
1020
],
[
1020,
24,
1311
]
],
[
[
1242,
24,
643
],
[
6... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Cetirizine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) i... | Cetirizine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Clonidine and Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Met... |
DB00312 | DB11986 | 1,023 | 484 | [
"DDInter1423",
"DDInter648"
] | Pentobarbital | Entrectinib | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
1023,
24,
484
]
],
[
[
1023,
24,
112
],
[
112,
23,
484
]
],
[
[
1023,
24,
466
],
[
466,
62,
484
]
],
[
[
1023,
24,
1320
],
[
1320,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]... | Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Darolutami... |
DB14360 | DB14491 | 822 | 428 | [
"DDInter1645",
"DDInter725"
] | Saw palmetto | Ferrous fumarate | Saw palmetto is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug. | Used in treatment of iron deficiency anemia. | Minor | 0 | [
[
[
822,
23,
428
]
],
[
[
822,
62,
1596
],
[
1596,
62,
1096
],
[
1096,
23,
428
]
],
[
[
822,
62,
1596
],
[
1596,
23,
1193
],
[
1193,
23,... | [
[
[
"Saw palmetto",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ferrous fumarate"
]
],
[
[
"Saw palmetto",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Iron"
],
[
... | Saw palmetto may cause a minor interaction that can limit clinical effects when taken with Iron and Iron may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ferrous fumarate
Sa... |
DB00086 | DB00814 | 1,167 | 1,171 | [
"DDInter1712",
"DDInter1143"
] | Streptokinase | Meloxicam | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
1167,
24,
1171
]
],
[
[
1167,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
1167,
25,
936
],
[
936,
63,
1171
]
],
[
[
1167,
24,
477
],
[
477,
... | [
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Streptokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
... | Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Streptokinase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate di... |
DB00270 | DB00757 | 1,428 | 1,166 | [
"DDInter993",
"DDInter581"
] | Isradipine | Dolasetron | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
1428,
25,
1166
]
],
[
[
1428,
6,
8374
],
[
8374,
45,
1166
]
],
[
[
1428,
21,
28803
],
[
28803,
60,
1166
]
],
[
[
1428,
24,
752
],
[
75... | [
[
[
"Isradipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Isradipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dolaset... | Isradipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dolasetron (Compound)
Isradipine (Compound) causes Anaemia (Side Effect) and Anaemia (Side Effect) is caused by Dolasetron (Compound)
Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidi... |
DB01281 | DB15091 | 881 | 676 | [
"DDInter5",
"DDInter1901"
] | Abatacept | Upadacitinib | Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1).[L20504,L42715] Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS mo... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
881,
25,
676
]
],
[
[
881,
23,
1193
],
[
1193,
23,
676
]
],
[
[
881,
62,
1461
],
[
1461,
23,
676
]
],
[
[
881,
24,
1430
],
[
1430,
... | [
[
[
"Abatacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Abatacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc glu... | Abatacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Abatacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitam... |
DB00060 | DB04835 | 912 | 1,655 | [
"DDInter947",
"DDInter1125"
] | Interferon beta-1a | Maraviroc | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Moderate | 1 | [
[
[
912,
24,
1655
]
],
[
[
912,
24,
1419
],
[
1419,
24,
1655
]
],
[
[
912,
24,
1468
],
[
1468,
63,
1655
]
],
[
[
912,
63,
1560
],
[
1560,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib ... |
DB00059 | DB00675 | 1,560 | 888 | [
"DDInter1404",
"DDInter1744"
] | Pegaspargase | Tamoxifen | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
1560,
24,
888
]
],
[
[
1560,
24,
303
],
[
303,
23,
888
]
],
[
[
1560,
24,
256
],
[
256,
62,
888
]
],
[
[
1560,
24,
1627
],
[
1627,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Medroxyprogesterone acet... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a minor interaction that can limit clinical effects when taken with Tamoxifen
Pegaspargase may cause a moderate interaction that could exacerbate diseases wh... |
DB00307 | DB11979 | 1,101 | 1,320 | [
"DDInter202",
"DDInter625"
] | Bexarotene | Elagolix | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the f... | Moderate | 1 | [
[
[
1101,
24,
1320
]
],
[
[
1101,
62,
168
],
[
168,
23,
1320
]
],
[
[
1101,
23,
271
],
[
271,
23,
1320
]
],
[
[
1101,
24,
1297
],
[
1297,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
... | Bexarotene may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Elagolix
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may... |
DB00400 | DB00834 | 353 | 932 | [
"DDInter843",
"DDInter1215"
] | Griseofulvin | Mifepristone | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercor... | Moderate | 1 | [
[
[
353,
24,
932
]
],
[
[
353,
6,
8374
],
[
8374,
45,
932
]
],
[
[
353,
21,
28762
],
[
28762,
60,
932
]
],
[
[
353,
62,
1101
],
[
1101,
... | [
[
[
"Griseofulvin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mifepristone"
]
],
[
[
"Griseofulvin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compo... | Griseofulvin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mifepristone (Compound)
Griseofulvin (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Mifepristone (Compound)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bexarotene an... |
DB00682 | DB12329 | 126 | 464 | [
"DDInter1951",
"DDInter660"
] | Warfarin | Eravacycline | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive aerobic, and facultative bacteria. This includes most of those bacteria resistant to cephalosporins, fluoroquin... | Moderate | 1 | [
[
[
126,
24,
464
]
],
[
[
126,
25,
609
],
[
609,
23,
464
]
],
[
[
126,
24,
384
],
[
384,
23,
464
]
],
[
[
126,
24,
1517
],
[
1517,
2... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eravacycline"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithr... | Warfarin may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Eravacycline
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may ca... |
DB00860 | DB00939 | 891 | 1,338 | [
"DDInter1513",
"DDInter1135"
] | Prednisolone | Meclofenamic acid | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis. | Moderate | 1 | [
[
[
891,
24,
1338
]
],
[
[
891,
24,
1479
],
[
1479,
63,
1338
]
],
[
[
891,
21,
28708
],
[
28708,
60,
1338
]
],
[
[
891,
40,
1573
],
[
1573... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meclofenamic acid"
]
],
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ... | Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid
Prednisolone (Compound) causes Malaise (Side Effect) and Malaise (Side Effect) is c... |
DB11817 | DB14443 | 1,259 | 987 | [
"DDInter165",
"DDInter1931"
] | Baricitinib | Vibrio cholerae CVD 103-HgR strain live antigen | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1259,
24,
987
]
],
[
[
1259,
64,
1480
],
[
1480,
24,
987
]
],
[
[
1259,
25,
1303
],
[
1303,
24,
987
]
],
[
[
1259,
25,
994
],
[
994,
... | [
[
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixa... | Baricitinib may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Baricitinib may lead to a major life threatening interaction when taken with Guselkumab and G... |
DB00285 | DB12500 | 1,100 | 283 | [
"DDInter1927",
"DDInter714"
] | Venlafaxine | Fedratinib | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorde... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
1100,
24,
283
]
],
[
[
1100,
24,
351
],
[
351,
23,
283
]
],
[
[
1100,
25,
1593
],
[
1593,
23,
283
]
],
[
[
1100,
24,
1419
],
[
1419,
... | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
... | Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Venlafaxine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause ... |
DB01253 | DB01364 | 628 | 22 | [
"DDInter664",
"DDInter650"
] | Ergometrine | Ephedrine | An ergot alkaloid with uterine and vascular smooth muscle contractile properties. | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Major | 2 | [
[
[
628,
25,
22
]
],
[
[
628,
64,
1445
],
[
1445,
1,
22
]
],
[
[
628,
6,
5214
],
[
5214,
45,
22
]
],
[
[
628,
21,
28653
],
[
28653,
... | [
[
[
"Ergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
]
],
[
[
"Ergometrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
... | Ergometrine may lead to a major life threatening interaction when taken with Pseudoephedrine and Pseudoephedrine (Compound) resembles Ephedrine (Compound)
Ergometrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Ephedrine (Compound)
Ergometrine (Compound) causes Bradycardia (Side Effect) and Bradycardia... |
DB00445 | DB00862 | 322 | 1,005 | [
"DDInter655",
"DDInter1918"
] | Epirubicin | Vardenafil | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, ... | Moderate | 1 | [
[
[
322,
24,
1005
]
],
[
[
322,
21,
28770
],
[
28770,
60,
1005
]
],
[
[
322,
23,
112
],
[
112,
63,
1005
]
],
[
[
322,
63,
1494
],
[
1494,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vardenafil"
]
],
[
[
"Epirubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Haematuria"
],
[
"Haematuria",
"{u} (Side Effect) is ca... | Epirubicin (Compound) causes Haematuria (Side Effect) and Haematuria (Side Effect) is caused by Vardenafil (Compound)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with V... |
DB00860 | DB00982 | 891 | 1,517 | [
"DDInter1513",
"DDInter991"
] | Prednisolone | Isotretinoin | Prednisolone is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects. Prednisolone was granted FDA approval on 21 June 1955. | Isotretinoin is a retinoid derivative of vitamin A used in the treatment of severe recalcitrant acne.[Label] It was most widely marketed under the brand name Accutane, which has since been discontinued. Isotretinoin is associated with major risks in pregnancy and is therefore only available under the iPLEDGE program in... | Moderate | 1 | [
[
[
891,
24,
1517
]
],
[
[
891,
18,
6168
],
[
6168,
46,
1517
]
],
[
[
891,
7,
10578
],
[
10578,
46,
1517
]
],
[
[
891,
18,
10375
],
[
1037... | [
[
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isotretinoin"
]
],
[
[
"Prednisolone",
"{u} (Compound) downregulates {v} (Gene)",
"IGFBP3"
],
[
"IGFBP3",
"{u} (Gene) is upregulated... | Prednisolone (Compound) downregulates IGFBP3 (Gene) and IGFBP3 (Gene) is upregulated by Isotretinoin (Compound)
Prednisolone (Compound) upregulates PRKAG2 (Gene) and PRKAG2 (Gene) is upregulated by Isotretinoin (Compound)
Prednisolone (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Isotreti... |
DB00489 | DB11363 | 17 | 1,276 | [
"DDInter1704",
"DDInter39"
] | Sotalol | Alectinib | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Alectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4 (echinoderm microtubule-associated protein-like 4) fusion protein that causes prol... | Moderate | 1 | [
[
[
17,
24,
1276
]
],
[
[
17,
1,
88
],
[
88,
24,
1276
]
],
[
[
17,
25,
1011
],
[
1011,
24,
1276
]
],
[
[
17,
64,
1424
],
[
1424,
24,... | [
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alectinib"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate inter... | Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Alectinib
Sotalol may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases w... |
DB00489 | DB09472 | 17 | 1,383 | [
"DDInter1704",
"DDInter1693"
] | Sotalol | Sodium sulfate | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Major | 2 | [
[
[
17,
25,
1383
]
],
[
[
17,
25,
609
],
[
609,
24,
1383
]
],
[
[
17,
64,
521
],
[
521,
24,
1383
]
],
[
[
17,
25,
971
],
[
971,
63,
... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
... | Sotalol may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Sotalol may lead to a major life threatening interaction when taken with Goserelin and Goserelin may cause a moderate ... |
DB00238 | DB08912 | 188 | 1,040 | [
"DDInter1285",
"DDInter462"
] | Nevirapine | Dabrafenib | A potent, non-nucleoside reverse transcriptase inhibitor (NNRTI) used in combination with nucleoside analogues for treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection and AIDS. Structurally, nevirapine belongs to the dipyridodiazepinone chemical class. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
188,
24,
1040
]
],
[
[
188,
6,
8374
],
[
8374,
45,
1040
]
],
[
[
188,
54,
19242
],
[
19242,
15,
1040
]
],
[
[
188,
21,
28900
],
[
2890... | [
[
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Nevirapine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Nevirapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dabrafenib (Compound)
Nevirapine (Compound) is included by Cytochrome P450 2B6 Inducers (Pharmacologic Class) and Cytochrome P450 2B6 Inducers (Pharmacologic Class) includes Dabrafenib (Compound)
Nevirapine (Compound) causes Abdominal pain (Side Ef... |
DB00682 | DB05294 | 126 | 1,069 | [
"DDInter1951",
"DDInter1917"
] | Warfarin | Vandetanib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
126,
24,
1069
]
],
[
[
126,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
126,
6,
1829
],
[
1829,
45,
1069
]
],
[
[
126,
24,
101
],
[
101,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Warfarin (Compound) binds ALB (Gene) and ALB (Gene) is bound by Vandetanib (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when ... |
DB00595 | DB09146 | 1,545 | 489 | [
"DDInter1374",
"DDInter978"
] | Oxytetracycline | Iron sucrose | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Iron sucrose (sucroferric oxyhydroxide or iron saccharate) is used as a source of iron in patients with iron deficiency anemia with chronic kidney disease (CKD), including those who are undergoing dialysis (hemodialysis or peritoneal) and those who do not require dialysis. Due to less side effects than iron dextran, ir... | Moderate | 1 | [
[
[
1545,
24,
489
]
],
[
[
1545,
24,
260
],
[
260,
63,
489
]
],
[
[
1545,
40,
1669
],
[
1669,
24,
489
]
],
[
[
1545,
24,
954
],
[
954,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron sucrose"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ferrous sulfate... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Ferrous sulfate anhydrous and Ferrous sulfate anhydrous may cause a moderate interaction that could exacerbate diseases when taken with Iron sucrose
Oxytetracycline (Compound) resembles Minocycline (Compound) and Minocycline... |
DB01098 | DB06186 | 14 | 1,439 | [
"DDInter1622",
"DDInter969"
] | Rosuvastatin | Ipilimumab | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin... | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Moderate | 1 | [
[
[
14,
24,
1439
]
],
[
[
14,
63,
912
],
[
912,
24,
1439
]
],
[
[
14,
24,
1060
],
[
1060,
63,
1439
]
],
[
[
14,
35,
788
],
[
788,
63... | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
... | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with E... |
DB00083 | DB01246 | 677 | 820 | [
"DDInter225",
"DDInter45"
] | Botulinum toxin type A | Alimemazine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
677,
24,
820
]
],
[
[
677,
24,
104
],
[
104,
40,
820
]
],
[
[
677,
24,
401
],
[
401,
24,
820
]
],
[
[
677,
24,
1511
],
[
1511,
6... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Me... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause ... |
DB06077 | DB08912 | 879 | 1,040 | [
"DDInter1102",
"DDInter462"
] | Lumateperone | Dabrafenib | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumatepero... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Major | 2 | [
[
[
879,
25,
1040
]
],
[
[
879,
64,
1101
],
[
1101,
23,
1040
]
],
[
[
879,
63,
478
],
[
478,
24,
1040
]
],
[
[
879,
24,
1478
],
[
1478,
... | [
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{... | Lumateperone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause ... |
DB11703 | DB12267 | 405 | 1,476 | [
"DDInter9",
"DDInter233"
] | Acalabrutinib | Brigatinib | To date, acalabrutinib has been used in trials studying the treatment of B-All, myelofibrosis, ovarian cancer, multiple myeloma, and Hodgkin lymphoma, among others. As of October 31, 2017 the FDA approved Astra Zeneca's orally administered Calquence (acalabrutinib, capsules). This Bruton tyrosine kinase (BTK) inhibitor... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
405,
24,
1476
]
],
[
[
405,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
405,
25,
800
],
[
800,
24,
1476
]
],
[
[
405,
64,
379
],
[
379,
... | [
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
... | Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Acalabrutinib may lead to a major life threatening interaction when taken with Duvelisib and Duvelisib may cause ... |
DB00782 | DB01142 | 1,123 | 1,264 | [
"DDInter1535",
"DDInter593"
] | Propantheline | Doxepin | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
1123,
24,
1264
]
],
[
[
1123,
63,
508
],
[
508,
24,
1264
]
],
[
[
1123,
24,
401
],
[
401,
24,
1264
]
],
[
[
1123,
24,
1405
],
[
1405,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Pro... |
DB00660 | DB00662 | 1,470 | 717 | [
"DDInter1163",
"DDInter1873"
] | Metaxalone | Trimethobenzamide | Metaxalone is a moderate to strong muscle relaxant used in the symptomatic treatment of musculoskeletal pain caused by strains, sprains, and other musculoskeletal conditions. It is marketed by King Pharmaceuticals under the brand name Skelaxin®. Its main mechanism of action is thought to involve general central nervous... | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Moderate | 1 | [
[
[
1470,
24,
717
]
],
[
[
1470,
21,
28762
],
[
28762,
60,
717
]
],
[
[
1470,
63,
1594
],
[
1594,
24,
717
]
],
[
[
1470,
24,
1376
],
[
137... | [
[
[
"Metaxalone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Metaxalone",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is... | Metaxalone (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Metaxalone may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tr... |
DB00008 | DB00011 | 491 | 1,451 | [
"DDInter1407",
"DDInter944"
] | Peginterferon alfa-2a | Interferon alfa-n1 | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Moderate | 1 | [
[
[
491,
24,
1451
]
],
[
[
491,
23,
450
],
[
450,
62,
1451
]
],
[
[
491,
24,
310
],
[
310,
63,
1451
]
],
[
[
491,
63,
1057
],
[
1057,
... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon alfa-n1"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
... | Peginterferon alfa-2a may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a minor interaction that can limit clinical effects when taken with Interferon alfa-n1
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases... |
DB01224 | DB09272 | 623 | 412 | [
"DDInter1553",
"DDInter632"
] | Quetiapine | Eluxadoline | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
623,
24,
412
]
],
[
[
623,
63,
1594
],
[
1594,
24,
412
]
],
[
[
623,
24,
830
],
[
830,
24,
412
]
],
[
[
623,
40,
252
],
[
252,
2... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine and Phe... |
DB00188 | DB01124 | 168 | 1,411 | [
"DDInter222",
"DDInter1828"
] | Bortezomib | Tolbutamide | Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest ... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
168,
24,
1411
]
],
[
[
168,
24,
959
],
[
959,
40,
1411
]
],
[
[
168,
6,
10215
],
[
10215,
45,
1411
]
],
[
[
168,
18,
3771
],
[
3771,
... | [
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Bortezomib (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Bortezomib (Compound) downregulates SUV39H1 (Gene) and SUV39H1 (... |
DB00562 | DB01132 | 1,014 | 1,130 | [
"DDInter188",
"DDInter1472"
] | Benzthiazide | Pioglitazone | Benzthiazide is used to treat hypertension and edema. Like other thiazides, benzthiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used... | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
1014,
24,
1130
]
],
[
[
1014,
1,
359
],
[
359,
24,
1130
]
],
[
[
1014,
24,
688
],
[
688,
24,
1130
]
],
[
[
1014,
63,
11
],
[
11,
... | [
[
[
"Benzthiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Benzthiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may c... | Benzthiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone
Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interact... |
DB01362 | DB14598 | 497 | 183 | [
"DDInter960",
"DDInter619"
] | Iohexol | Edetate calcium disodium anhydrous | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Edetate calcium disodium is a metal ion chelator used to reduce blood concentrations and depot stores of lead from the body. It is on the World Health Organization Model List of Essential Medicines. Edetate calcium disodium was granted FDA approval on 16 July 1953. | Major | 2 | [
[
[
497,
25,
183
]
],
[
[
497,
64,
372
],
[
372,
24,
183
]
],
[
[
497,
1,
258
],
[
258,
25,
183
]
],
[
[
497,
64,
372
],
[
372,
25,
... | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edetate calcium disodium anhydrous"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofarabine"
],
[
"Clofar... | Iohexol may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Edetate calcium disodium anhydrous
Iohexol (Compound) resembles Iodixanol (Compound) and Iodixanol may lead to a major life threatening int... |
DB00526 | DB00543 | 1,555 | 87 | [
"DDInter1355",
"DDInter82"
] | Oxaliplatin | Amoxapine | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
1555,
24,
87
]
],
[
[
1555,
24,
623
],
[
623,
40,
87
]
],
[
[
1555,
64,
695
],
[
695,
40,
87
]
],
[
[
1555,
63,
867
],
[
867,
1,... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Oxaliplatin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound)
Oxaliplatin may c... |
DB00912 | DB01261 | 473 | 170 | [
"DDInter1581",
"DDInter1679"
] | Repaglinide | Sitagliptin | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
473,
24,
170
]
],
[
[
473,
5,
11640
],
[
11640,
44,
170
]
],
[
[
473,
6,
3486
],
[
3486,
45,
170
]
],
[
[
473,
21,
28850
],
[
28850,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Repaglinide",
"{u} (Compound) treats {v} (Disease)",
"type 2 diabetes mellitus"
],
[
"type 2 diabetes mellitus",
... | Repaglinide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Sitagliptin (Compound)
Repaglinide (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Sitagliptin (Compound)
Repaglinide (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) i... |
DB00250 | DB08912 | 10 | 1,040 | [
"DDInter475",
"DDInter462"
] | Dapsone | Dabrafenib | A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of m... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Moderate | 1 | [
[
[
10,
24,
1040
]
],
[
[
10,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
10,
21,
28900
],
[
28900,
60,
1040
]
],
[
[
10,
63,
168
],
[
168,
... | [
[
[
"Dapsone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Dapsone",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Dapsone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Dapsone (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Dabrafenib (Compound)
Dapsone may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bor... |
DB00912 | DB02546 | 473 | 137 | [
"DDInter1581",
"DDInter1947"
] | Repaglinide | Vorinostat | Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
473,
24,
137
]
],
[
[
473,
21,
28898
],
[
28898,
60,
137
]
],
[
[
473,
24,
1344
],
[
1344,
63,
137
]
],
[
[
473,
24,
1130
],
[
1130,
... | [
[
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Repaglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Constipation"
],
[
"Constipation",
"{u} (Side Effect)... | Repaglinide (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Vorinostat (Compound)
Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin may cause a moderate interaction that could exacerbate diseases when take... |
DB00927 | DB04948 | 1,559 | 1,084 | [
"DDInter712",
"DDInter1083"
] | Famotidine | Lofexidine | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1559,
24,
1084
]
],
[
[
1559,
62,
112
],
[
112,
23,
1084
]
],
[
[
1559,
63,
618
],
[
618,
24,
1084
]
],
[
[
1559,
24,
774
],
[
774,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Famotidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Famotidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarel... |
DB00877 | DB11569 | 629 | 1,093 | [
"DDInter1678",
"DDInter1003"
] | Sirolimus | Ixekizumab | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflamma... | Moderate | 1 | [
[
[
629,
24,
1093
]
],
[
[
629,
23,
1114
],
[
1114,
23,
1093
]
],
[
[
629,
62,
1461
],
[
1461,
23,
1093
]
],
[
[
629,
63,
608
],
[
608,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
]
],
[
[
"Sirolimus",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc sulfate"
],
[
... | Sirolimus may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a minor interaction that can limit clinical effects when taken with Ixekizumab
Sirolimus may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E m... |
DB00451 | DB00619 | 542 | 1,419 | [
"DDInter1064",
"DDInter909"
] | Levothyroxine | Imatinib | Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland. Also known as L-thyroxine or the brand name product Synthroid, levothyroxine is used primarily to treat hypothyroidism, a condition where the thyroid gland is no longer able to produce sufficient quant... | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Moderate | 1 | [
[
[
542,
24,
1419
]
],
[
[
542,
6,
4973
],
[
4973,
45,
1419
]
],
[
[
542,
18,
7247
],
[
7247,
57,
1419
]
],
[
[
542,
21,
28762
],
[
28762,... | [
[
[
"Levothyroxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
]
],
[
[
"Levothyroxine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)... | Levothyroxine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Imatinib (Compound)
Levothyroxine (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Imatinib (Compound)
Levothyroxine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Imatinib (Compound)
Lev... |
DB00342 | DB00744 | 1,181 | 1,288 | [
"DDInter1770",
"DDInter1962"
] | Terfenadine | Zileuton | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, a... | Major | 2 | [
[
[
1181,
25,
1288
]
],
[
[
1181,
24,
1297
],
[
1297,
63,
1288
]
],
[
[
1181,
25,
868
],
[
868,
63,
1288
]
],
[
[
1181,
24,
1419
],
[
1419... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zileuton"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodro... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Zileuton
Terfenadine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may ... |
DB09472 | DB11640 | 1,383 | 1,267 | [
"DDInter1693",
"DDInter64"
] | Sodium sulfate | Amifampridine | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Amifampridine, or 3,4-diaminopyridine (3,4-DAP), is a quaternary ammonium compound that blocks presynaptic potassium channels, and subsequently prolongs the action potential and increases presynaptic calcium concentrations . It was first discovered in Scotland in the 1970s and its clinical effectiveness for neuromuscul... | Moderate | 1 | [
[
[
1383,
24,
1267
]
],
[
[
1383,
24,
407
],
[
407,
24,
1267
]
],
[
[
1383,
63,
999
],
[
999,
24,
1267
]
],
[
[
1383,
24,
913
],
[
913,
... | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
... | Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and... |
DB06779 | DB08896 | 365 | 292 | [
"DDInter470",
"DDInter1576"
] | Dalteparin | Regorafenib | Dalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the r... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
365,
25,
292
]
],
[
[
365,
63,
643
],
[
643,
24,
292
]
],
[
[
365,
24,
637
],
[
637,
24,
292
]
],
[
[
365,
24,
41
],
[
41,
63,
... | [
[
[
"Dalteparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"Desve... | Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase... |
DB00342 | DB06288 | 1,181 | 607 | [
"DDInter1770",
"DDInter77"
] | Terfenadine | Amisulpride | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Amisulpride is a benzamide derivative and a dopamine receptor antagonist that selectively works on dopamine D2 and D3 receptors. As an antipsychotic agent, amisulpride alleviates both positive and negative symptoms of schizophrenia, and it exhibits antidepressant properties in patients with psychiatric disorders, dysth... | Major | 2 | [
[
[
1181,
25,
607
]
],
[
[
1181,
23,
112
],
[
112,
23,
607
]
],
[
[
1181,
24,
1559
],
[
1559,
24,
607
]
],
[
[
1181,
25,
1383
],
[
1383,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amisulpride"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Terfenadine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amisulpride
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and F... |
DB01224 | DB12332 | 623 | 1,619 | [
"DDInter1553",
"DDInter1626"
] | Quetiapine | Rucaparib | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
623,
24,
1619
]
],
[
[
623,
62,
112
],
[
112,
23,
1619
]
],
[
[
623,
40,
87
],
[
87,
24,
1619
]
],
[
[
623,
24,
1662
],
[
1662,
... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Quetiapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Quetiapine (Compound) resembles Amoxapine (Compound) and Amoxapine may cause a moderate interaction that could ... |
DB00283 | DB09061 | 701 | 1,627 | [
"DDInter395",
"DDInter284"
] | Clemastine | Cannabidiol | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Moderate | 1 | [
[
[
701,
24,
1627
]
],
[
[
701,
35,
1594
],
[
1594,
24,
1627
]
],
[
[
701,
24,
662
],
[
662,
24,
1627
]
],
[
[
701,
24,
407
],
[
407,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Clemastine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken ... | Clemastine (Compound) resembles Doxylamine (Compound) and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Clemastine may cause a moderate interaction that coul... |
DB00304 | DB00673 | 1,657 | 723 | [
"DDInter508",
"DDInter112"
] | Desogestrel | Aprepitant | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
1657,
24,
723
]
],
[
[
1657,
21,
28847
],
[
28847,
60,
723
]
],
[
[
1657,
25,
1101
],
[
1101,
23,
723
]
],
[
[
1657,
24,
392
],
[
392,... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Desogestrel",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect)... | Desogestrel (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Aprepitant (Compound)
Desogestrel may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Aprepitant
Desog... |
DB00514 | DB00835 | 506 | 100 | [
"DDInter527",
"DDInter245"
] | Dextromethorphan | Brompheniramine | Dextromethorphan is a levorphanol derivative and codeine analog commonly used as a cough suppressant and also a drug of abuse. Although similar in structure to other opioids, it has minimal interaction with opioid receptors. Dextromethorphan was granted FDA approval before 3 December 1957.[A215412,L14997] | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Moderate | 1 | [
[
[
506,
24,
100
]
],
[
[
506,
24,
832
],
[
832,
24,
100
]
],
[
[
506,
63,
508
],
[
508,
24,
100
]
],
[
[
506,
24,
649
],
[
649,
63,... | [
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
]
],
[
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tripelenna... | Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine
Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken w... |
DB01209 | DB09272 | 1,359 | 412 | [
"DDInter531",
"DDInter632"
] | Dezocine | Eluxadoline | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system ... | Moderate | 1 | [
[
[
1359,
24,
412
]
],
[
[
1359,
63,
1594
],
[
1594,
24,
412
]
],
[
[
1359,
24,
849
],
[
849,
24,
412
]
],
[
[
1359,
64,
475
],
[
475,
... | [
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eluxadoline"
]
],
[
[
"Dezocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
... | Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Eluxadoline
Dezocine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramin... |
DB00850 | DB08938 | 1,630 | 1,384 | [
"DDInter1432",
"DDInter1112"
] | Perphenazine | Magaldrate | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1630,
23,
1384
]
],
[
[
1630,
1,
1178
],
[
1178,
23,
1384
]
],
[
[
1630,
35,
401
],
[
401,
23,
1384
]
],
[
[
1630,
24,
1559
],
[
1559,... | [
[
[
"Perphenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Trifluoperazine"
],
[
"Trifluoperazine",
"{u} may cau... | Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Perphenazine (Compound) resembles Promethazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00013 | DB04896 | 1,255 | 901 | [
"DDInter1905",
"DDInter1220"
] | Urokinase | Milnacipran | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the a... | Moderate | 1 | [
[
[
1255,
24,
901
]
],
[
[
1255,
24,
41
],
[
41,
1,
901
]
],
[
[
1255,
25,
405
],
[
405,
63,
901
]
],
[
[
1255,
25,
500
],
[
500,
24... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Urokinase may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could... |
DB01224 | DB09043 | 623 | 135 | [
"DDInter1553",
"DDInter36"
] | Quetiapine | Albiglutide | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
623,
24,
135
]
],
[
[
623,
63,
126
],
[
126,
23,
135
]
],
[
[
623,
63,
176
],
[
176,
24,
135
]
],
[
[
623,
24,
820
],
[
820,
24,... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insul... |
DB00620 | DB01045 | 175 | 463 | [
"DDInter1855",
"DDInter1590"
] | Triamcinolone | Rifampicin | Triamcinolone is a corticosteroid used to treat various inflammatory conditions in the body from allergic rhinitis to acute exacerbations of multiple sclerosis. Triamcinolone can be used as a one time adjunct treatment of osteoarthritic knee pain, or first line as a topical treatment of corticosteroid responsive dermat... | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Moderate | 1 | [
[
[
175,
24,
463
]
],
[
[
175,
63,
690
],
[
690,
40,
463
]
],
[
[
175,
6,
8374
],
[
8374,
45,
463
]
],
[
[
175,
63,
1101
],
[
1101,
... | [
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifampicin"
]
],
[
[
"Triamcinolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rifabutin"
],
... | Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Rifabutin and Rifabutin (Compound) resembles Rifampicin (Compound)
Triamcinolone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rifampicin (Compound)
Triamcinolone may cause a moderate interaction that could exac... |
DB00313 | DB00748 | 556 | 662 | [
"DDInter1913",
"DDInter297"
] | Valproic acid | Carbinoxamine | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the... | Moderate | 1 | [
[
[
556,
24,
662
]
],
[
[
556,
24,
1594
],
[
1594,
24,
662
]
],
[
[
556,
6,
6017
],
[
6017,
45,
662
]
],
[
[
556,
21,
28921
],
[
28921,
... | [
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
]
],
[
[
"Valproic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],... | Valproic acid may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine
Valproic acid (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Carbinoxamine (Compound)
Valpro... |
DB00563 | DB01219 | 663 | 716 | [
"DDInter1174",
"DDInter473"
] | Methotrexate | Dantrolene | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
663,
24,
716
]
],
[
[
663,
5,
11594
],
[
11594,
49,
716
]
],
[
[
663,
21,
28698
],
[
28698,
60,
716
]
],
[
[
663,
24,
267
],
[
267,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Methotrexate",
"{u} (Compound) treats {v} (Disease)",
"multiple sclerosis"
],
[
"multiple sclerosis",
"{u} (Di... | Methotrexate (Compound) treats multiple sclerosis (Disease) and multiple sclerosis (Disease) is palliated by Dantrolene (Compound)
Methotrexate (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Methotrexate may cause a moderate interaction that could exacerbate disea... |
DB00582 | DB04845 | 1,622 | 309 | [
"DDInter1946",
"DDInter1001"
] | Voriconazole | Ixabepilone | Voriconazole (Vfend, Pfizer) is a triazole antifungal medication used to treat serious fungal infections. It is used to treat invasive fungal infections that are generally seen in patients who are immunocompromised. These include invasive candidiasis, invasive aspergillosis, and emerging fungal infections. The increase... | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. ... | Moderate | 1 | [
[
[
1622,
24,
309
]
],
[
[
1622,
6,
8374
],
[
8374,
45,
309
]
],
[
[
1622,
21,
28987
],
[
28987,
60,
309
]
],
[
[
1622,
24,
1419
],
[
1419... | [
[
[
"Voriconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
]
],
[
[
"Voriconazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compou... | Voriconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ixabepilone (Compound)
Voriconazole (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Ixabepilone (Compound)
Voriconazole may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imat... |
DB00782 | DB11130 | 1,123 | 407 | [
"DDInter1535",
"DDInter1344"
] | Propantheline | Opium | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1123,
24,
407
]
],
[
[
1123,
63,
662
],
[
662,
24,
407
]
],
[
[
1123,
24,
1054
],
[
1054,
24,
407
]
],
[
[
1123,
62,
685
],
[
685,
... | [
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Propantheline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Kaolin and Kao... |
DB00196 | DB09034 | 600 | 1,313 | [
"DDInter743",
"DDInter1733"
] | Fluconazole | Suvorexant | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Major | 2 | [
[
[
600,
25,
1313
]
],
[
[
600,
25,
1135
],
[
1135,
62,
1313
]
],
[
[
600,
24,
1213
],
[
1213,
24,
1313
]
],
[
[
600,
24,
1619
],
[
1619,
... | [
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Suvorexant"
]
],
[
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} m... | Fluconazole may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Suvorexant
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a mo... |
DB06754 | DB14730 | 707 | 1,412 | [
"DDInter471",
"DDInter264"
] | Danaparoid | Calaspargase pegol | Danaparoid is a low-molecular-weight heparinoid with an average molecular weight of 5500 Daltons consisting of a mixture of glycosaminoglycans. The active constituents are heparan, dermatan and, and they are isolated from the porcine intestinal mucosa [FDA Label]. Danaparoid possesses a potent antithrombic activity tha... | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparagina... | Moderate | 1 | [
[
[
707,
24,
1412
]
],
[
[
707,
64,
792
],
[
792,
24,
1412
]
],
[
[
707,
24,
1496
],
[
1496,
24,
1412
]
],
[
[
707,
25,
365
],
[
365,
... | [
[
[
"Danaparoid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Danaparoid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"R... | Danaparoid may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib ... |
DB00557 | DB09078 | 252 | 1,228 | [
"DDInter895",
"DDInter1036"
] | Hydroxyzine | Lenvatinib | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
252,
24,
1228
]
],
[
[
252,
23,
112
],
[
112,
23,
1228
]
],
[
[
252,
24,
609
],
[
609,
24,
1228
]
],
[
[
252,
24,
603
],
[
603,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Hydroxyzine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Hydroxyzine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin an... |
DB01035 | DB01246 | 1,401 | 820 | [
"DDInter1524",
"DDInter45"
] | Procainamide | Alimemazine | A derivative of procaine with less CNS action. | A phenothiazine derivative that is used as an antipruritic. | Major | 2 | [
[
[
1401,
25,
820
]
],
[
[
1401,
25,
401
],
[
401,
24,
820
]
],
[
[
1401,
21,
28751
],
[
28751,
60,
820
]
],
[
[
1401,
24,
286
],
[
286,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Alimemazine"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
... | Procainamide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Procainamide (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Alimemazine (Compound)... |
DB00350 | DB00408 | 1,214 | 1,408 | [
"DDInter1226",
"DDInter1099"
] | Minoxidil | Loxapine | A potent direct-acting peripheral vasodilator (vasodilator agents) that reduces peripheral resistance and produces a fall in blood pressure. | An antipsychotic agent used in schizophrenia. [PubChem] | Moderate | 1 | [
[
[
1214,
24,
1408
]
],
[
[
1214,
63,
902
],
[
902,
40,
1408
]
],
[
[
1214,
24,
1119
],
[
1119,
1,
1408
]
],
[
[
1214,
24,
695
],
[
695,
... | [
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loxapine"
]
],
[
[
"Minoxidil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clobazam"
],
[
"C... | Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Clobazam and Clobazam (Compound) resembles Loxapine (Compound)
Minoxidil may cause a moderate interaction that could exacerbate diseases when taken with Chlordiazepoxide and Chlordiazepoxide (Compound) resembles Loxapine (Compound... |
DB00405 | DB00844 | 128 | 314 | [
"DDInter517",
"DDInter1257"
] | Dexbrompheniramine | Nalbuphine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
128,
24,
314
]
],
[
[
128,
24,
828
],
[
828,
40,
314
]
],
[
[
128,
63,
421
],
[
421,
1,
314
]
],
[
[
128,
63,
475
],
[
475,
25,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Na... |
DB01396 | DB11348 | 1,482 | 1,065 | [
"DDInter553",
"DDInter279"
] | Digitoxin | Calcium Phosphate | A cardiac glycoside sometimes used in place of digoxin. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1482,
24,
1065
]
],
[
[
1482,
63,
1620
],
[
1620,
24,
1065
]
],
[
[
1482,
40,
1252
],
[
1252,
24,
1065
]
],
[
[
1482,
63,
1620
],
[
16... | [
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
],
... | Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline and Tetracycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Digitoxin (Compound) resembles Digoxin (Compound) and Digoxin may cause a moderate interaction that co... |
DB00420 | DB00927 | 508 | 1,559 | [
"DDInter1532",
"DDInter712"
] | Promazine | Famotidine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Moderate | 1 | [
[
[
508,
24,
1559
]
],
[
[
508,
6,
10215
],
[
10215,
45,
1559
]
],
[
[
508,
18,
1918
],
[
1918,
57,
1559
]
],
[
[
508,
24,
286
],
[
286,
... | [
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
]
],
[
[
"Promazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",... | Promazine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Famotidine (Compound)
Promazine (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Famotidine (Compound)
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnes... |
DB00081 | DB09068 | 273 | 1,427 | [
"DDInter1838",
"DDInter1948"
] | Tositumomab | Vortioxetine | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Vortioxetine is an antidepressant medication indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and stimulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin r... | Moderate | 1 | [
[
[
273,
24,
1427
]
],
[
[
273,
25,
256
],
[
256,
24,
1427
]
],
[
[
273,
64,
366
],
[
366,
24,
1427
]
],
[
[
273,
25,
405
],
[
405,
... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugr... | Tositumomab may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Tositumomab may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderat... |
DB00046 | DB00489 | 1,179 | 17 | [
"DDInter940",
"DDInter1704"
] | Insulin lispro | Sotalol | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Moderate | 1 | [
[
[
1179,
24,
17
]
],
[
[
1179,
24,
88
],
[
88,
40,
17
]
],
[
[
1179,
24,
417
],
[
417,
23,
17
]
],
[
[
1179,
24,
1479
],
[
1479,
62... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sotalol"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol (Compound) resembles Sotalol (Compound)
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Sucralfate and Sucralfate may cause a minor interaction that can... |
DB05578 | DB11866 | 330 | 1,068 | [
"DDInter1566",
"DDInter1618"
] | Ramucirumab | Romosozumab | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stim... | Romosozumab is a humanized monoclonal antibody indicated for the treatment of osteoperosis in postmenopausal women at high risk of fracture and patients who have failed in other treatments or are intolerant to other osteoperosis therapies. Romosozumab prevents bone resorption and induces the formation of bone though it... | Moderate | 1 | [
[
[
330,
24,
1068
]
],
[
[
330,
25,
1618
],
[
1618,
24,
1068
]
],
[
[
330,
64,
1213
],
[
1213,
24,
1068
]
],
[
[
330,
25,
1618
],
[
1618,
... | [
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romosozumab"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Caboz... | Ramucirumab may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Romosozumab
Ramucirumab may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate... |
DB01082 | DB12615 | 1,448 | 1,381 | [
"DDInter1713",
"DDInter1482"
] | Streptomycin | Plazomicin | Streptomycin, an antibiotic derived from _Streptomyces griseus_, was the first aminoglycoside to be discovered and used in practice in the 1940s.[A233325,A233390] Selman Waksman and eventually Albert Schatz were recognized with the Nobel Prize in Medicine for their discovery of streptomycin and its antibacterial activi... | Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from . The structure of plazomicin was established via appending hydroxylaminobutyric acid to at position 1 and 2-hydroxyethyl group at position 6' . It was designed to evade all clinically relevant aminoglyco... | Moderate | 1 | [
[
[
1448,
24,
1381
]
],
[
[
1448,
62,
608
],
[
608,
23,
1381
]
],
[
[
1448,
63,
1479
],
[
1479,
24,
1381
]
],
[
[
1448,
24,
101
],
[
101,
... | [
[
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plazomicin"
]
],
[
[
"Streptomycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Streptomycin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Plazomicin
Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid an... |
DB05316 | DB09082 | 749 | 659 | [
"DDInter1467",
"DDInter1934"
] | Pimavanserin | Vilanterol | Pimavanserin is an atypical antipsychotic indicated for the treatment of psychiatric disorders. Although the exact mechanism of action is unknown, it is thought that pimavanserin interacts with the serotonin receptors, particularly the 5-HT<sub>2A</sub> and HT<sub>2C</sub> receptors. Unlike other atypical antipsychotic... | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
749,
24,
659
]
],
[
[
749,
63,
1220
],
[
1220,
23,
659
]
],
[
[
749,
24,
927
],
[
927,
63,
659
]
],
[
[
749,
64,
1069
],
[
1069,
... | [
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Pimavanserin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Pimavanserin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib a... |
DB09046 | DB12825 | 1,094 | 1,375 | [
"DDInter1201",
"DDInter1032"
] | Metreleptin | Lefamulin | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1094,
24,
1375
]
],
[
[
1094,
24,
159
],
[
159,
63,
1375
]
],
[
[
1094,
24,
1320
],
[
1320,
24,
1375
]
],
[
[
1094,
63,
1419
],
[
1419... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and E... |
DB08882 | DB12825 | 1,281 | 1,375 | [
"DDInter1070",
"DDInter1032"
] | Linagliptin | Lefamulin | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin w... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1281,
24,
1375
]
],
[
[
1281,
63,
966
],
[
966,
24,
1375
]
],
[
[
1281,
64,
1101
],
[
1101,
24,
1375
]
],
[
[
1281,
24,
659
],
[
659,
... | [
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
... | Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Linagliptin may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause... |
DB00694 | DB11601 | 51 | 1,270 | [
"DDInter485",
"DDInter1889"
] | Daunorubicin | Tuberculin purified protein derivative | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycoba... | Moderate | 1 | [
[
[
51,
24,
1270
]
],
[
[
51,
64,
550
],
[
550,
24,
1270
]
],
[
[
51,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
51,
63,
1555
],
[
1555,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzuma... | Daunorubicin may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ca... |
DB06343 | DB06655 | 1,379 | 5 | [
"DDInter1766",
"DDInter1077"
] | Teprotumumab | Liraglutide | Teprotumumab is a fully human IgG1 monoclonal antibody directed against the human insulin-like growth factor-1 receptor. Following a clinical trial in which its efficacy in the treatment of thyroid eye disease (TED) was assessed, it received "breakthrough therapy" designation from the FDA in 2016 and was approved by th... | Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist.[Label,A6932] Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmit... | Moderate | 1 | [
[
[
1379,
24,
5
]
],
[
[
1379,
63,
245
],
[
245,
24,
5
]
],
[
[
1379,
24,
1296
],
[
1296,
63,
5
]
],
[
[
1379,
63,
245
],
[
245,
23,... | [
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liraglutide"
]
],
[
[
"Teprotumumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
... | Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Liraglutide
Teprotumumab may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglud... |
DB00790 | DB06691 | 664 | 849 | [
"DDInter1431",
"DDInter1155"
] | Perindopril | Mepyramine | Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible fo... | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
664,
24,
849
]
],
[
[
664,
63,
1648
],
[
1648,
24,
849
]
],
[
[
664,
24,
407
],
[
407,
63,
849
]
],
[
[
664,
24,
1376
],
[
1376,
... | [
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Perindopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[... | Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Perindopril may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.